@tmharbison - For NDMM, frontline therapy typically involves induction with a triplet or quadruplet regimen (e.g., bortezomib, lenalidomide, dexamethasone [VRd] or daratumumab, bortezomib, lenalidomide, dexamethasone [D-VRd]), followed by ASCT for transplant-eligible patients, and maintenance therapy (e.g., lenalidomide). ASCT remains the standard of care for fit, newly diagnosed patients up to age 70–75, as it deepens responses and extends progression-free survival (PFS). However, CAR T-cell therapies and bsAbs, which have transformed relapsed/refractory MM (RRMM), are being investigated for NDMM to potentially replace or complement ASCT, especially for high-risk patients.